Last reviewed · How we verify
Tetanus Day 29
Tetanus Day 29 is a Biologic drug developed by Providence Health & Services. It is currently in Phase 1 development. Also known as: Tetanus Toxoid, Tetanus Toxoid Adsorbed.
There is no verified information available about Tetanus Day 29. However, based on the provided facts, Tetanus Antitoxin is a protein-based intervention, as indicated by its listing in ChEMBL, and it has been studied in various clinical trials, including those registered on ClinicalTrials.gov.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Tetanus Day 29 |
|---|---|
| Also known as | Tetanus Toxoid, Tetanus Toxoid Adsorbed |
| Sponsor | Providence Health & Services |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Maternal Determinants of Infant Immunity to Pertussis (PHASE4)
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (PHASE1)
- Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer (PHASE1)
- Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma (PHASE1, PHASE2)
- Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma (PHASE2)
- Vaccine Therapy in Treating Patients With Advanced Melanoma (PHASE1)
- A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tetanus Day 29 CI brief — competitive landscape report
- Tetanus Day 29 updates RSS · CI watch RSS
- Providence Health & Services portfolio CI
Frequently asked questions about Tetanus Day 29
What is Tetanus Day 29?
Who makes Tetanus Day 29?
Is Tetanus Day 29 also known as anything else?
What development phase is Tetanus Day 29 in?
Related
- Manufacturer: Providence Health & Services — full pipeline
- Also known as: Tetanus Toxoid, Tetanus Toxoid Adsorbed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing